StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)

Close on Nov 13, 2026Market cap $5.30BP/E –Yield –

Earnings

PTC Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$358.00M
+69.7% on a year earlier
EPS, Q3 FY2026
–
$0.20 a year earlier
Latest guidance
Issued
Oct 29, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of PTC Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Jan 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026after the close$358.00M+69.7%–Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$272.55M–-$0.03Release
Q4 FY2025ended Dec 31, 2025Jan 12, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$211.00M+7.2%$0.20Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$178.90M-4.2%-$0.83Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$213.20M-30.6%–Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$196.80M+0.1%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$186.70M-12.7%-$1.29Release
Q1 FY2024ended Mar 31, 2024Apr 25, 2024after the close$210.10M-4.7%–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

PTC Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Expected total revenueFY2026$1.18B – $1.28B$1.08B – $1.18BRaisedJul 30, 2026
product revenue growthFY2026+19% – +36%–NewJan 12, 2026
total revenueFY2026$1.29B – $1.32B–NewOct 29, 2026
GAAP R&D and SG&A expenseGAAPFY2026$775.00M – $815.00M–NewOct 29, 2026
GAAP R&D and SG&A expenseGAAPFY2026$775.00M – $815.00M$775.00M – $815.00MReaffirmedJul 30, 2026
Non-GAAP R&D and SG&A expensenon-GAAPFY2026$680.00M – $720.00M–NewOct 29, 2026
Non-GAAP R&D and SG&A expensenon-GAAPFY2026$680.00M – $720.00M$680.00M – $720.00MReaffirmedJul 30, 2026

Guidance history

Every forecast PTC Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026GAAP R&D and SG&A expenseFY2026$775.00M – $815.00MNew
Oct 29, 2026Non-GAAP R&D and SG&A expenseFY2026$680.00M – $720.00MNew
Oct 29, 2026total revenueFY2026$1.29B – $1.32BNew
Jul 30, 2026Non-GAAP R&D and SG&A expenseFY2026$680.00M – $720.00MReaffirmed
Jul 30, 2026GAAP R&D and SG&A expenseFY2026$775.00M – $815.00MReaffirmed
Jul 30, 2026Expected total revenueFY2026$1.18B – $1.28BRaised
Jul 30, 2026t otal product revenueFY2026$850.00M – $950.00MLowered
May 7, 2026Non-GAAP R&D and SG&A expenseFY2026$680.00M – $720.00MReaffirmed
May 7, 2026GAAP R&D and SG&A expenseFY2026$775.00M – $815.00MReaffirmed
May 7, 2026total revenueFY2026$1.08B – $1.18BRaised
May 7, 2026Total product revenueFY2026$750.00M – $850.00MRaised
Jan 12, 2026Non-GAAP R&D and SG&A expenseFY2026$680.00M – $720.00MNew
Jan 12, 2026GAAP R&D and SG&A expenseFY2026$775.00M – $815.00MNew
Jan 12, 2026Total product revenueFY2026$700.00M – $800.00MNew
Jan 12, 2026product revenue growthFY2026+19% – +36%New
Nov 4, 2025Non-GAAP R&D and SG&A expenseFY2025$730.00M – $760.00MNew
Nov 4, 2025GAAP R&D and SG&A expenseFY2025$805.00M – $835.00MNew
Nov 4, 2025Total revenueFY2025$750.00M – $800.00MNew
Aug 7, 2025non-GAAP R&D and SG&A expenseFY2025$730.00M – $760.00MReaffirmed
Aug 7, 2025GAAP R&D and SG&A expenseFY2025$805.00M – $835.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases PTC Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. PTC Therapeutics Board of Directors Authorizes $500 Million
    Update
  2. PTC Therapeutics Provides Corporate Update
    Results
  3. Quarterly results release
    Results
  4. PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
    Update
  5. PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
    Update
  6. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    Results
  7. PTC Therapeutics Announces Pricing of Convertible
    News
  8. PTC Therapeutics Provides Corporate Update
    Results
  9. PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
    Update
  10. PIVOT-HD LTE 24-Month Interim Analysis Results
    Update
  11. PTC Therapeutics Appoints Biotech Banking Pioneer
    Update
  12. PTC Therapeutics Provides Corporate Update and
    Results
  13. PTC Therapeutics Provides Regulatory Update on Translarna™
    Update
  14. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
    Results
  15. J.P. Morgan 2026 Healthcare Conference
    Results

See a number that looks wrong?